Talk:Inclisiran

Leads are intended to summarise article content
As this is WP policy/guideline content, the sentence on mechanism of action of this agent, unique to the lead, was reproduced in the main body in a new section. Citations were moved there, with the editing summary noting that one of more might be moved back to the lead, if other editors think necessary. (If their appearance at end of sentence properly indicated that they were all in support of just that sentence, then it is sufficient that they were moved with the sentence into the text.) Then, section titles were edited, to indicate the paragraph following was focused on clinical history, and that further content on the history and science of the agent's discovery would be appropriate in the new section.

On a separate matter, I would note that using a standard infobox field that indicates the "Formula" of siRNA agents are singular rubbish (apologies to those believing and maintaining such). I say this, because such representations are meaningless, and should be replaced by useful information, such as is descriptive of the agent/target sequences at which the therapeutic takes aim. (Or not, it it is too much technical bother. It is understood that this venue is amateur description, and not intended as fully useful content.) Cheers. 2601:246:C700:14C:8135:8ED:FD9A:C2B4 (talk) 23:20, 28 August 2022 (UTC)

Side effects
Since we don't have a side effects section, I assume we should say that this drug is part of the black triangle scheme in the UK, but I don't have a good source for that. CV9933 (talk) 15:18, 16 April 2024 (UTC)